Humoral Hypercalcemia Of Malignancy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for humoral hypercalcemia of malignancy. 36 active patents protecting 4 drugs from 2+ originators. First major cliff: 2032. Daily refresh.

4
Approved drugs
36
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Humoral Hypercalcemia Of Malignancy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 33 patents Novartis 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating humoral hypercalcemia of malignancy. Each bar = one year. Y-axis scaled to peak year (7 patents).

5
27
5
28
2
30
5
32
4
33
7
34
1
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03
Zometa
ZOLEDRONIC ACID
 Novartis 3 65 — 2028-02-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
7932241 Zometa other 75 2028-08-05
12133914 Cortef method of use 75 2043-02-23
11904046 Cortef method of use 75 2043-02-23
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
9717740 Cortef method of use 62 2032-11-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10022502 Decadron method of use 45 2034-06-22
10028965 Decadron method of use 45 2034-05-23
8563027 Decadron method of use 51 2030-02-12
11097061 Decadron method of use 53 2039-06-23
11304961 Decadron method of use 53 2037-12-18

Related